Roche Launches New DNA Sequencing Platform AXELIOS 1
Roche has launched AXELIOS 1, a single-molecule sequencing platform that uses sequencing by expansion technology to deliver same-day whole-genome results.
Roche has launched AXELIOS 1, a single-molecule sequencing platform that uses sequencing by expansion technology to deliver same-day whole-genome results.
The clinician-ordered test integrates polygenic risk scores validated in over 236,000 participants from the NIH's All of Us Research Program.
New whole exome and transcriptome sequencing assay demonstrates high concordance with existing companion diagnostics while requiring minimal tissue input for biomarker detection.
NGS-based MRD testing offers unprecedented sensitivity and breadth in detecting low-frequency leukemic clones.
Read MoremNGS significantly improves pathogen detection in pulmonary infections, enabling more precision compared to conventional methods.
Read MoreNeoGenomics and Ultima Genomics have partnered to use the UG 100 sequencing platform to advance precision oncology diagnostics.
Read MoreBruker announced major advancements at ESCMID Global, including expanded PCR assay options for its BeGenius system.
Read MoreThermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit, an NGS hybrid capture assay.
Read MoreChildren’s Hospital Colorado’s new in-house whole-genome sequencing lab is revolutionizing patient care by making genetic testing faster.
Read MoreUltima Genomics has launched UG 100 Solaris, an upgraded sequencing solution that enhances throughput and reduces costs.
Read MoreResearchers have developed a revolutionary method using DNA sequencing to rapidly and precisely measure metabolites critical for health.
Read MoreBaylor Genetics has partnered with Epic’s Aura diagnostics suite, enabling ordering genetic tests and access results directly within the EHR.
Read MoreDatar Cancer Genetics introduced a blood test that combines tumor-agnostic NGS and tumor-informed dd-PCR to detect MRD.
Read MoreResearchers demonstrate the potential of long-read sequencing to diagnose rare genetic diseases faster and more accurately.
Read MoreOGT’s SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.
Read MoreWhile serving the region, Doylestown Health has a small clinical laboratory. To better serve its community, it added NGS in 2023.Â
Read MoreTwo studies demonstrate the potential of a genomic screening platform to improve early detection of genetic diseases in newborns.
Read MoreDelve Bio’s Delve Detect is a metagenomic sequencing test capable of quickly identifying over 68,000 pathogens from CSF.
Read More